



Mersana Therapeutics to Present at the 8th Annual SVB Leerink Global Healthcare Conference

February 20, 2019

CAMBRIDGE, Mass., Feb. 20, 2019 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc., (NASDAQ:MRSN) a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody drug conjugates (ADCs) targeting cancers in areas of high unmet need, today announced that Anna Protopapas, President and Chief Executive Officer, will present a company overview at the 8th Annual SVB Leerink Global Healthcare Conference in New York City, NY on Wednesday, February 27, 2019 at 11:30 a.m. ET.

A live webcast of the presentation will be available on the Investors & Media section of Mersana's website at www.mersana.com. Archived replays will be available for approximately 90 days following the presentation.

About Mersana Therapeutics

Mersana Therapeutics is a clinical-stage biopharmaceutical company using its differentiated and proprietary ADC platforms to develop highly targeted drugs with increased tolerability and expanded opportunities to deliver meaningful clinical benefit to patients. Mersana's lead product candidate, XMT-1536, is in a Phase 1 clinical trial in patients with tumors expressing NaPi2b, including ovarian cancer, NSCLC, and other cancers. In addition, multiple partners are using Mersana's platform to advance their ADC pipelines.

Contacts:

Investor Contact

Sarah Carmody, 617-844-8577

scarmody@mersana.com

Media Contact

Paul Kidwell, 617-680-1088

pkidwell@mersana.com



Source: Mersana Therapeutics, Inc.